Choice of antithrombotic therapy in atrial fibrillation, a daily challenge. No convincing evidence that warfarin is better than acetylsalicylic acid
Current guidelines relating to the primary prevention of stroke in non-valvular atrial fibrillation are primarily based on randomised trials comparing warfarin with placebo. Warfarin is recommended in the majority of patients. However, weaknesses in the design and performance of these trials tend to overestimate the treatment effect. Furthermore, the inclusion of highly selected patients with a low percentage of elderly subjects, low bleeding risk, short follow-up periods and high discontinuation rates makes it impossible to generalize the results and apply them to general practice. Trials directly comparing warfarin with aspirin are the most reliable when it comes to comparing treatment efficacy. These trials have included a similar number of patients but a larger percentage of elderly patients and they comprise more years of observation and end-point events compared with the placebo-controlled warfarin trials. The results show that warfarin is not convincingly superior to aspirin in terms of stroke prevention. Warfarin can only be recommended in patients with a high risk of thromboembolic events.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2003 |
|---|---|
| Erschienen: |
2003 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:100 |
|---|---|
| Enthalten in: |
Lakartidningen - 100(2003), 34 vom: 21. Aug., Seite 2597-9, 2602-4 |
| Sprache: |
Schwedisch |
|---|
| Weiterer Titel: |
Val av antitrombotisk behandling vid förmaksflimmer, ett dagligt huvudbry. Ingen övertygande evidens för att warfarin är bättre än acetylsalicylsyra |
|---|
| Beteiligte Personen: |
Mooe, Thomas [VerfasserIn] |
|---|
| Themen: |
5Q7ZVV76EI |
|---|
| Anmerkungen: |
Date Completed 17.10.2003 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM127155325 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM127155325 | ||
| 003 | DE-627 | ||
| 005 | 20231222213358.0 | ||
| 007 | tu | ||
| 008 | 231222s2003 xx ||||| 00| ||swe c | ||
| 028 | 5 | 2 | |a pubmed24n0424.xml |
| 035 | |a (DE-627)NLM127155325 | ||
| 035 | |a (NLM)12968319 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a swe | ||
| 100 | 1 | |a Mooe, Thomas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Choice of antithrombotic therapy in atrial fibrillation, a daily challenge. No convincing evidence that warfarin is better than acetylsalicylic acid |
| 246 | 3 | 3 | |a Val av antitrombotisk behandling vid förmaksflimmer, ett dagligt huvudbry. Ingen övertygande evidens för att warfarin är bättre än acetylsalicylsyra |
| 264 | 1 | |c 2003 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 17.10.2003 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Current guidelines relating to the primary prevention of stroke in non-valvular atrial fibrillation are primarily based on randomised trials comparing warfarin with placebo. Warfarin is recommended in the majority of patients. However, weaknesses in the design and performance of these trials tend to overestimate the treatment effect. Furthermore, the inclusion of highly selected patients with a low percentage of elderly subjects, low bleeding risk, short follow-up periods and high discontinuation rates makes it impossible to generalize the results and apply them to general practice. Trials directly comparing warfarin with aspirin are the most reliable when it comes to comparing treatment efficacy. These trials have included a similar number of patients but a larger percentage of elderly patients and they comprise more years of observation and end-point events compared with the placebo-controlled warfarin trials. The results show that warfarin is not convincingly superior to aspirin in terms of stroke prevention. Warfarin can only be recommended in patients with a high risk of thromboembolic events | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Warfarin |2 NLM | |
| 650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Lakartidningen |d 1965 |g 100(2003), 34 vom: 21. Aug., Seite 2597-9, 2602-4 |w (DE-627)NLM000007544 |x 1652-7518 |7 nnns |
| 773 | 1 | 8 | |g volume:100 |g year:2003 |g number:34 |g day:21 |g month:08 |g pages:2597-9, 2602-4 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 100 |j 2003 |e 34 |b 21 |c 08 |h 2597-9, 2602-4 | ||